Literature DB >> 16313549

Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.

D Henley1, J Kaye, J Walsh, G Cull.   

Abstract

We report three cases of severe hypocalcaemia associated with i.v. bisphosphonate treatment in patients with multiple myeloma. All patients had symptomatic hypocalcaemia, including a tonic-clonic seizure and tachyarrhythmia in one case. Two cases were associated with the development of acute renal failure, whereas the third patient had pre-existing renal impairment. We recommend that bisphosphonates be used with caution in patients with myeloma and renal impairment, that vitamin D deficiency be corrected prior to treatment (to reduce the risk of hypocalcaemia) and that serum calcium and renal function be monitored during treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16313549     DOI: 10.1111/j.1445-5994.2005.00949.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  4 in total

Review 1.  Drug-induced endocrine and metabolic disorders.

Authors:  Ronald C W Ma; Alice P S Kong; Norman Chan; Peter C Y Tong; Juliana C N Chan
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

2.  Effect of intravenous hydration in patients receiving bisphosphonate therapy.

Authors:  David Attivi; Gaétan Kosmalski; Claire Zeghmouli; Stéphane Gibaud
Journal:  Int J Clin Pharm       Date:  2014-09-10

3.  Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report.

Authors:  Adrian P Noriega Aldave; Shikha Jaiswal
Journal:  J Med Case Rep       Date:  2014-10-23

4.  Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.

Authors:  Sahar M Nasser; Arwa Sahal; Anas Hamad; Shereen Elazzazy
Journal:  J Oncol Pharm Pract       Date:  2019-01-07       Impact factor: 1.809

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.